Dupont And Amgen: Lab Partners?

When it comes to spotting the next big takeover, all eyes are on DuPont. It's no secret that the chemical giant wants to expand its life-sciences unit through an acquisition. On May 19, DuPont agreed to pay $2.6 billion for Merck's 50% stake in a joint venture the two companies formed in 1991 to research drugs against AIDS, cancer, and heart disease. The talk on the Street is that DuPont will go after Monsanto or Britain's Zeneca. But some investors are betting DuPont's target is Amgen (AMGN), the world's top independent biotech company.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.